Tanhuo Decoction for Acute Coronary Syndrome With Cerebral Atherosclerosis in Elderly Patients

Starting soon · Not applicable

Conditions studied: Acute Coronary Syndrome Comorbid With Cerebral Atherosclerosis

In brief

The goal of this clinical trial is to learn if Tanhuo decoction works to treat acute coronary syndrome combined with cerebral atherosclerosis in the elderly. It will also learn about the safety of Tanhuo decoction. The main questions it aims to answer are: Can Tanhuo decoction reduce inflammatory markers in elderly patients with acute coronary syndrome combined with cerebral atherosclerosis and decrease the occurrence of adverse cardiovascular events? What medical problems do participants have when taking Tanhuo decoction? Researchers will compare Tanhuo decoction to a placebo (a look-alike substance that contains no drug) to see if Tanhuo decoction works to treat acute coronary syndrome combined with cerebral atherosclerosis in the elderly. Participants will:Take Tanhuo decoction or a placebo every day for a week. undergo laboratory tests and echocardiography at baseline (before starting the medication), on day 7, and at 1 month after initiation, and will complete telephone follow-ups during hospitalization and at 1, 3, 6, and 12 months after discharge.

Key facts

Study ID

NCT07445581

Run by

Jinggang Xia, MD

People needed

480

Starts

2026-02-28

Expected to finish

2027-12-31

Last updated by the study team

2026-03-03

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hemodynamic stability within 24 hours following treatment for acute coronary syndrome
• A confirmed prior diagnosis of ischemic cerebrovascular disease, or the presence of intracranial or extracranial arterial stenosis ≥50%, as verified by carotid and cerebrovascular ultrasound after admission
• Manifestations consistent with fire-heat syndrome, including tongue body appearance, tongue coating, stool characteristics, mental state, facial complexion, breathing pattern, presence of fever, pulse features, oral sensation, and urine properties. A total score of ≥7 points based on the weighted scoring system for each item indicates the presence of fire-heat syndrome.
• Age ≥ 60 years old

You may not qualify if…

• Patients with persistent hemodynamic instability beyond 24 hours, or those with ACS-related hypotension (SBP < 90 mmHg or DBP < 60 mmHg), or requiring coronary artery bypass grafting based on coronary artery lesions
• History of chronic heart failure due to any cause
• History of ischemic stroke, peptic ulcer, active bleeding, or major surgery within the past 3 months
• Hepatic or renal dysfunction, defined as ALT or AST levels >5 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m²
• Previous history of bronchial asthma
• Platelet count <80×10⁹/L or anemia (hemoglobin ≤100 g/L)
• Contraindication or allergy to aspirin, clopidogrel, ticagrelor, or statins
• History of malignant tumor
• Known allergy to components of traditional Chinese medicine

Where it is running

• Xuanwu Hospital of Capital Medical University — Beijing, Beijing Municipality, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.